Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies
Sign Up to like & getrecommendations! Published in 2024 at "Advances in Therapy"
DOI: 10.1007/s12325-024-03073-8
Abstract: This study evaluated the safety and tolerability of fezolinetant in women with vasomotor symptoms (VMS) due to menopause in a pooled analysis of data from three 52-week phase 3 studies (SKYLIGHT 1, 2, and 4).… read more here.
Keywords: treatment; vasomotor symptoms; due menopause; menopause pooled ... See more keywords